Corium International (NASDAQ: CORI) is one of 103 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Corium International to related businesses based on the strength of its earnings, dividends, institutional ownership, valuation, risk, profitability and analyst recommendations.


This table compares Corium International and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corium International -149.99% -612.73% -64.69%
Corium International Competitors -2,402.47% -68.58% -7.25%

Valuation and Earnings

This table compares Corium International and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Corium International $31.86 million -$47.79 million -6.44
Corium International Competitors $8.17 billion $1.09 billion 152.98

Corium International’s peers have higher revenue and earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings for Corium International and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corium International 0 0 7 0 3.00
Corium International Competitors 873 3797 6767 181 2.54

Corium International currently has a consensus target price of $13.17, indicating a potential upside of 22.37%. As a group, “Pharmaceuticals” companies have a potential upside of 26.34%. Given Corium International’s peers higher probable upside, analysts clearly believe Corium International has less favorable growth aspects than its peers.

Volatility and Risk

Corium International has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Corium International’s peers have a beta of 34.60, indicating that their average stock price is 3,360% more volatile than the S&P 500.

Institutional & Insider Ownership

89.4% of Corium International shares are owned by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 45.7% of Corium International shares are owned by insiders. Comparatively, 11.4% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


Corium International peers beat Corium International on 7 of the 12 factors compared.

Corium International Company Profile

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with's FREE daily email newsletter.